STOCK TITAN

Cocrystal Pharma Inc - COCP STOCK NEWS

Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.

Cocrystal Pharma Inc. (COCP) provides this comprehensive news resource for tracking developments in its antiviral therapeutics pipeline. Access official press releases and verified updates on clinical trials, regulatory milestones, and strategic partnerships.

This page serves investors and industry observers seeking timely information about COCP's structure-based drug discovery platform and pipeline progress. Find updates on hepatitis C inhibitors, broad-spectrum influenza treatments, and norovirus antiviral candidates currently in development.

Content includes FDA correspondence, intellectual property filings, preclinical study results, and collaboration announcements with pharmaceutical partners. All materials are sourced directly from company disclosures to ensure regulatory compliance and factual accuracy.

Bookmark this page for consolidated access to Cocrystal Pharma's latest scientific advancements and business developments. Check regularly for updates on their mission to address unmet needs in viral disease treatment through innovative small-molecule therapeutics.

Rhea-AI Summary

Cocrystal Pharma (COCP) reported its Q3 2020 results, revealing a revenue of $489,000, slightly down from $492,000 year-over-year. The company closed the quarter with $31.8 million in cash, enabling the expansion of COVID-19 and Influenza A programs. Key developments include positive in vitro data for lead molecule CC-42344 against influenza and ongoing collaborations with Merck for influenza antiviral agents. Net losses increased to $2.67 million, reflecting higher R&D expenses due to COVID-19 initiatives. The company anticipates advancing its IND-enabling studies and initiating Phase 1 trials in 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced that Dr. Gary Wilcox and Dr. Sam Lee will present at the World Antiviral Conference on November 12, 2020, at 1:20 PM EST. Their presentation will cover novel antiviral therapeutics targeting coronaviruses and influenza A strains. Cocrystal's proprietary technology aims to develop broad-spectrum influenza antivirals and COVID-19 treatments, with promising in vitro activity against SARS-CoV-2. The company expects to choose its lead preclinical molecule by year-end 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced a presentation at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 12:00 PM EST. The management team will also hold virtual one-on-one meetings with registered investors at the event. A live video webcast will be accessible through the company's website, with a replay available two hours post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
conferences
Rhea-AI Summary

Cocrystal Pharma (NASDAQ: COCP) announced promising in vitro data for its influenza A drug candidate CC-42344. The compound demonstrated antiviral activity against a resistant H1N1 strain, retaining a potency of 0.5 nM. Ongoing IND-enabling studies show a favorable safety profile, with a no adverse effect level exceeding 1,000 mg/kg in rat and dog studies. Cocrystal plans to finalize the Phase 1 study protocol and begin clinical trials in 2021, aiming to address concerns over seasonal and pandemic influenza.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced a proposed settlement of a derivative action in the U.S. District Court, New Jersey. The settlement aims to resolve claims against individual defendants, requiring certain corporate governance enhancements by Cocrystal. It includes a payment of $275,000 to cover plaintiffs' legal fees and service awards. Current stockholders as of August 20, 2020, are barred from contesting the settlement once approved. A hearing is scheduled for December 16, 2020, to evaluate the fairness of the settlement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma (NASDAQ: COCP) will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 3:30 PM EDT, led by Chairman and CEO Dr. Gary Wilcox. The presentation will be followed by virtual one-on-one meetings with qualified investors. A live video webcast will be available on the Company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
conferences
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced the completion of a public offering of 16,422,813 shares at $1.05 each, raising approximately $17.2 million before expenses. The offering included the partial exercise of an underwriter's option for an additional 2,137,098 shares. Proceeds will fund the expansion of Cocrystal's development programs for COVID-19 and Influenza, as well as general corporate purposes. H.C. Wainwright & Co. managed the offering under a previously filed shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced an increased public offering of 14,285,715 shares of common stock at $1.05 per share, aiming to raise approximately $15.0 million before discounts and commissions. The offering, set to close around August 31, 2020, is to support the expansion of COVID-19 and Influenza treatment programs. H.C. Wainwright & Co. is the sole book-running manager for this offering. The company has also granted a 30-day option to purchase an additional 2,142,857 shares at the same price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
none
-
Rhea-AI Summary

Cocrystal Pharma, Inc. (NASDAQ: COCP) announced an underwriting agreement with H.C. Wainwright & Co. to sell 9,523,810 shares at $1.05 each, expected to close around August 31, 2020. The offering aims to raise approximately $10 million to fund COVID-19 and influenza treatment development. An additional 1,428,571 shares may be purchased by the underwriter within 30 days. This offering is part of a previously filed shelf registration. The company specializes in developing antiviral therapeutics targeting various viruses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.53%
Tags
none
Rhea-AI Summary

Cocrystal Pharma (NASDAQ: COCP) announced its Q2 2020 financial results and program updates. The company has expanded its license with Kansas State University for broad-spectrum antiviral compounds against Coronavirus and published findings showing potent in vitro inhibition of the virus. Cocrystal reported revenues of $554,000 for Q2 2020, down from $592,000 in Q2 2019, while general and administrative expenses rose to $2,028,000. Net loss surged to $3,495,000 compared to a loss of $1,515,000 in the same quarter last year. As of June 30, 2020, cash on hand was approximately $19.37 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags

FAQ

What is the current stock price of Cocrystal Pharma (COCP)?

The current stock price of Cocrystal Pharma (COCP) is $1.65 as of April 28, 2025.

What is the market cap of Cocrystal Pharma (COCP)?

The market cap of Cocrystal Pharma (COCP) is approximately 13.6M.
Cocrystal Pharma Inc

Nasdaq:COCP

COCP Rankings

COCP Stock Data

13.59M
6.46M
31.85%
6.99%
0.16%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOTHELL